Transcriptomic Study of B-cell associated X (BAX) and B-cell lymphoma (BCL2) Protein in Breast Cancer

Background: Cancer is one of the major human problems and breast cancer is a significant health problem. In spite of the developed treatment methods, breast cancer cannot be treated very effectively. Therefore, the identification of novel genes that will have played a role in the treatment and diagnosis of breast cancer and the high interest of B-cell lymphoma (BCL2) family proteins are critical regulators of apoptosis). Objective: The current study aimed to investigate the relationship between the levels of BCL2, BAX, and B-cell integrate medium (BIM) proteins which the prognosis and apoptosis processes of the breast cell line. Patients and Methods: Collected tissue samples from normal and cancer tissue type, RNA isolated from the cell, then quantitation done, cDNA synthesized, cDNA quantitation and Real-time PCR was performed to see the level between two kinds of genes. Results: BCL2 protein level was significantly lessened in regulator molecule tissues of a cell line with breast cancer. In contrast to Bax protein, no significant difference was detected in the BIM expression level. Our result also showed that low BCL2 expression level is associated with significant clinical characteristics of the patient such as tumor grade, stage and breast cancer type. Conclusion: Findings of our study showed that BCL2 has a role in breast cancer formation and might be a novel biomarker for the diagnosis and treatment of breast cancer